NASDAQ:EXEL - Exelixis Stock Price, News & Analysis

$20.62
-0.88 (-4.09 %)
(As of 08/22/2019 04:00 PM ET)
Today's Range
$20.60
Now: $20.62
$21.56
50-Day Range
$19.60
MA: $20.94
$22.29
52-Week Range
$13.42
Now: $20.62
$25.31
Volume2.47 million shs
Average Volume3.23 million shs
Market Capitalization$6.25 billion
P/E Ratio14.42
Dividend YieldN/A
Beta1.98
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$853.83 million
Cash Flow$1.3811 per share
Book Value$4.91 per share

Profitability

Net Income$690.07 million

Miscellaneous

Employees484
Market Cap$6.25 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.


Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its earnings results on Wednesday, July, 31st. The biotechnology company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.02. The biotechnology company had revenue of $240.28 million for the quarter, compared to analyst estimates of $226.97 million. Exelixis had a return on equity of 31.31% and a net margin of 70.52%. The firm's revenue was up 29.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.31 EPS. View Exelixis' Earnings History.

When is Exelixis' next earnings date?

Exelixis is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Exelixis.

What price target have analysts set for EXEL?

8 equities research analysts have issued twelve-month price targets for Exelixis' shares. Their predictions range from $22.00 to $48.00. On average, they expect Exelixis' share price to reach $28.4286 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View Analyst Price Targets for Exelixis.

What is the consensus analysts' recommendation for Exelixis?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.

Has Exelixis been receiving favorable news coverage?

News articles about EXEL stock have trended positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Exelixis earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Exelixis.

Who are some of Exelixis' key competitors?

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Incyte (INCY), Gilead Sciences (GILD), Intel (INTC), BioMarin Pharmaceutical (BMRN), Celgene (CELG) and Puma Biotechnology (PBYI).

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:
  • Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.13%), Vanguard Group Inc. (9.17%), Meditor Group Ltd (4.97%), AQR Capital Management LLC (4.52%), Renaissance Technologies LLC (4.44%) and JPMorgan Chase & Co. (2.62%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Which major investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., Invesco Ltd., Canada Pension Plan Investment Board, Morgan Stanley, BlackRock Inc. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Which major investors are buying Exelixis stock?

EXEL stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, Prudential Financial Inc., Fiera Capital Corp, Marshall Wace LLP and First Trust Advisors LP. View Insider Buying and Selling for Exelixis.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $20.62.

How big of a company is Exelixis?

Exelixis has a market capitalization of $6.25 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.

What is Exelixis' official website?

The official website for Exelixis is http://www.exelixis.com/.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]


MarketBeat Community Rating for Exelixis (NASDAQ EXEL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  413 (Vote Outperform)
Underperform Votes:  366 (Vote Underperform)
Total Votes:  779
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2019 by MarketBeat.com Staff

Featured Article: Green Investing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel